Regenxbio
RGNX
187 hedge funds and large institutions have $1.24B invested in Regenxbio in 2020 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 50 increasing their positions, 62 reducing their positions, and 18 closing their positions.
200% more call options, than puts
Call options by funds: $15.7M | Put options by funds: $5.24M
117% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 18
58% more capital invested
Capital invested by funds: $784M → $1.24B (+$455M)
13% more funds holding
Funds holding: 166 → 187 (+21)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
3.22% less ownership
Funds ownership: 76.29% → 73.08% (-3.2%)
19% less repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 62
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$21.5M |
| 2 |
First Manhattan
New York
|
+$9.08M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$7.39M |
| 4 |
Goldman Sachs
New York
|
+$6.86M |
| 5 |
FM
Frazier Management
Seattle,
Washington
|
+$5.86M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$16.3M |
| 2 |
State Street
Boston,
Massachusetts
|
-$11.3M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$7.94M |
| 4 |
BlackRock
New York
|
-$7.8M |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$7.79M |
RGNX Hedge Fund Activity: Q4 2020 in Review
187 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Regenxbio (RGNX) for Q4 2020, worth a combined $1.24B — up 58% from $784M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new RGNX positions and 18 closed out — a net gain of 21 holders — while 50 added to existing stakes and 62 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $21.5M. The largest seller was Credit Suisse, cutting an estimated $16.3M.
- 187 institutional investors held Regenxbio (RGNX) as of Q4 2020, up from 166 in Q3 2020.
- Funds reported $1.24B of Regenxbio stock for Q4 2020, up 58% quarter-over-quarter.
- 39 funds opened new Regenxbio positions in Q4 2020 and 18 closed out, a net change of +21 holders.
- The largest Regenxbio buyer in Q4 2020 was JP Morgan Chase, an estimated $21.5M added.
- The largest Regenxbio seller in Q4 2020 was Credit Suisse, an estimated $16.3M sold.
Based on aggregated 13F filings for Q4 2020.